Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation

Kidney Transplant Clinical Trial

Official title:

Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06288152
• Other study ID #: STS-Transplant
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 1, 2024
• Est. completion date: March 1, 2027

Study information

• Verified date: February 2024
• Source: Lawson Health Research Institute
• Contact: Cadence Baker
• Phone: 519-685-8500
• Email: cadence.baker[@]lhsc.on.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

End-stage renal disease (ESRD) is a significant clinical problem for which dialysis or transplantation is required. The current need for kidneys for transplantation vastly exceeds the supply available from live donors, necessitating the use of kidneys from deceased donors. However, kidneys from deceased donors are associated with reduced viability, as lack of blood supply upon cardiac death increases tissue damage. In addition, the standard protocol for cold preservation of donor kidneys between procurement and transplantation increases the risk of delayed donor kidney function by 23% for every 6-hours of storage. Moreover, compared to other organs, the kidney is particularly prone to transplantation-induced injury due to its high metabolic activities and oxygen consumption. Hence, any minor disturbances in blood supply can easily lead to kidney injury. Therefore, it is not surprising that deceased donor kidneys have a low tolerance for damage associated with lack of blood supply. The focus of the investigators research has been to pioneer the development and supplementation of existing kidney preservation solutions with novel hydrogen sulfide (H2S) donor molecules to improve kidney viability for clinical transplantation. Specifically, the investigators demonstrated that supplementation of standard kidney preservation solutions with non-clinically viable H2S donor molecules significantly increased donor kidney protection and prolonged transplant recipient survival in murine and porcine models of kidney transplantation. Having shown the same salutary effect using sodium thiosulfate (STS; a clinically viable H2S donor drug) in rat kidney transplantation, the investigators aim to repeat this work using STS in porcine and clinical kidney transplantation.

This single-blind study will enroll participants receiving a kidney transplant. Through randomization, half of the participants will receive STS through administration into the pump the kidney is placed on after procurement from the donor and before transplant to the recipient. Participants will be followed for 1-year post transplant where blood and urine will be collected to determine graft function.

Description:

Full description pending

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: March 1, 2027
• Est. primary completion date: March 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age and over

• End-Stage Renal Disease

• Receiving a kidney transplant from a deceased donor (NDD or DCD)

Exclusion Criteria:

• Under 18 years of age

• Inability to provide informed consent

• Living donor kidney recipients

• Pregnant individuals

• Known allergy to study medication or its components (non-medicinal ingredients)

• Multiorgan transplant patients such as simultaneous kidney pancreas or liver kidney transplants

• Currently enrolled in another interventional transplant clinical trial, or another clinical trial that in the opinion of the QI and PI would greatly impact the results of this study.

Related Conditions & MeSH terms

• Kidney Transplant
• Renal Transplant

Intervention

Drug:
• Sodium Thiosulfate
0.15 mL administered

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Alp Sener

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effects of STS will be measured by: Delayed graft function	Number of participants requiring dialysis use post-transplant	1 year